Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Ends PARP Inhibitor Collaboration With Inotek

This article was originally published in The Pink Sheet Daily

Executive Summary

Inotek focuses on two clinical candidates and consolidating operations.

You may also be interested in...



Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Genentech Gains PARP Inhibitor Through Inotek Deal

The lead product, INO-1001, is in Phase Ib for malignant melanoma.

Topics

UsernamePublicRestriction

Register

PS067718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel